A cold-shock protein known as RBM3 — which has been shown to reinvigorate synapses and slow dementia onset in mice — was found in the blood of regular winter swimmers at an open-air unheated pool in London. (BBC, Nature)
Plasma p-tau217 increased during early Alzheimer’s disease and could be used to monitor disease progression. (Brain)
University of Miami researchers identified novel gene risk loci and pathways for Alzheimer’s among African Americans. (JAMA Neurology)
The investigational therapy Anavex 2-73 (blarcamesine) was safe and led to dose-dependent cognitive improvements in a phase II study of Parkinson’s disease dementia, Anavex Life Sciences said.
Air pollution was tied to an increased risk of hospital admission for Parkinson’s or Alzheimer’s and related dementia in an analysis of Medicare beneficiaries that spanned 17 years and 63 million older adults. (Lancet Planetary Health)
Is gene therapy ready for autism? (Spectrum)
COVID-19-related olfactory dysfunction had a pooled prevalence of 77% in studies that quantified smell loss, but only 44% in studies that relied on qualitative assessments and self-reports. (Chemical Senses)
Adults with mitochondrial diseases were more likely to have sleep-disordered breathing than the general population. (Neurology)
The FDA put Voyager Therapeutics’ investigational new drug submission for Huntington’s disease gene therapy on hold due to issues with chemistry, manufacturing, and controls, the company reported.
Pitolisant (Wakix) was approved for a new indication, cataplexy in adults with narcolepsy, said drugmaker Harmony Biosciences.
Diabetes patients treated with GLP-1 agonists or DPP4 inhibitors had a lower risk of Parkinson’s disease than those treated with other anti-diabetic agents. (Brain)
An analyst convened a mock advisory panel for Biogen’s controversial Alzheimer’s drug candidate aducanumab — which goes before a real FDA advisory committee in a few weeks — and the drug went down for the count. (Investor’s Business Daily)